These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25715308)

  • 1. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trimetazidine in the prevention of contrast-induced nephropathy in chronic kidney disease.
    Ibrahim TA; El-Mawardy RH; El-Serafy AS; El-Fekky EM
    Cardiovasc Revasc Med; 2017; 18(5):315-319. PubMed ID: 28532702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effect of trimetazidine on prevention of contrast-induced nephropathy in patients with renal insufficiency: An updated systematic review and meta-analysis.
    Ye Z; Lu H; Su Q; Guo W; Dai W; Li H; Yang H; Li L
    Medicine (Baltimore); 2017 Mar; 96(9):e6059. PubMed ID: 28248861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures.
    Onbasili AO; Yeniceriglu Y; Agaoglu P; Karul A; Tekten T; Akar H; Discigil G
    Heart; 2007 Jun; 93(6):698-702. PubMed ID: 17065180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).
    Heshmatzadeh Behzadi A; Amoozgar B; Jain S; Velasco N; Zahid U; Abbasi H; Alasadi L; Prince MR
    Medicine (Baltimore); 2021 Mar; 100(10):e24603. PubMed ID: 33725824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram.
    Rahman MM; Haque SS; Rokeya B; Siddique MA; Banerjee SK; Ahsan SA; Rahman F; Mahmood M; Ahmed K; Bhuiyan MM; Joarder AI; Debnath RC
    Mymensingh Med J; 2012 Apr; 21(2):292-9. PubMed ID: 22561774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coenzyme Q10 combined with trimetazidine in the prevention of contrast-induced nephropathy in patients with coronary heart disease complicated with renal dysfunction undergoing elective cardiac catheterization: a randomized control study and in vivo study.
    Chen F; Liu F; Lu J; Yang X; Xiao B; Jin Y; Zhang J
    Eur J Med Res; 2018 May; 23(1):23. PubMed ID: 29776437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials.
    Liu YH; Liu Y; Duan CY; Tan N; Chen JY; Zhou YL; Li LW; He PC
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):181-92. PubMed ID: 25193735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trimetazidine Prevention of Contrast-Induced Nephropathy in Coronary Angiography.
    Liu W; Ming Q; Shen J; Wei Y; Li W; Chen W; Xu Y
    Am J Med Sci; 2015 Nov; 350(5):398-402. PubMed ID: 26445302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimetazidine can prevent the occurrence of contrast-induced nephropathy after percutaneous coronary intervention in elderly patients with renal insufficiency.
    Fu H; Zhang J; Zhang H; Zhang P; Fu X; Zeng Z; Zhang X; Li W; Yang S; Liu X; Fu N
    Perfusion; 2021 Sep; 36(6):603-609. PubMed ID: 32909511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of NaCl saline hydration and N-Acetyl Cysteine to prevent contrast induced nephropathy in different populations of patients at high and low risk undergoing coronary artery angiography.
    Calabrò P; Bianchi R; Caprile M; Sordelli C; Cappelli Bigazzi M; Palmieri R; Gigantino G; Limongelli G; Capozzi G; Cuomo S; Calabrò R
    Minerva Cardioangiol; 2010 Feb; 58(1):35-40. PubMed ID: 20145594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
    Habib M; Hillis A; Hammad A
    Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of trimetazidine on incidence of myocardial injury and contrast-induced nephropathy in diabetic patients with renal dysfunction undergoing elective percutaneous coronary intervention.
    Shehata M
    Am J Cardiol; 2014 Aug; 114(3):389-94. PubMed ID: 24927970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
    Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
    Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
    Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
    Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    Kang X; Hu DY; Li CB; Ai ZS; Peng A
    Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of trimetazidine on preventing contrast-induced nephropathy after cardiac catheterization.
    Lian X; He W; Zhan H; Chen J; Tan N; He P; Liu Y
    Int Urol Nephrol; 2019 Dec; 51(12):2267-2272. PubMed ID: 31641999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.